NCT06764303View on ClinicalTrials.gov

A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

July 8, 2025

Study Completion Date

July 8, 2027

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

NTQ5082 100mg qd

NTQ5082 100mg qd

DRUG

NTQ5082 200mg qd

NTQ5082 200mg qd

Trial Locations (2)

250033

Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin

310012

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
lead

Nanjing Chia-tai Tianqing Pharmaceutical

INDUSTRY